Management of Dementia With Olive Oil Leaves - GOLDEN

Study Overview
=================
Brief Summary
-----------------
Mild Dementia (Mild Dementia) is a state of mind disorder (memory, reason, attention, concentration, time orientation) with difficulty in the complex activities of everyday life (bank accounts, shopping, transportation, etc).The olive leaves contain several phenolic compounds, most important of which are oleo-European and hydroxytyrosol. The properties of the olive leaves have been attributed mainly to these two substances.

Detailed Description
-----------------
Mild Dementia (Mild Dementia) is a state of mind disorder (memory, reason, attention, concentration, time orientation) with difficulty in the complex activities of everyday life (bank accounts, shopping, transportation, etc) The olive leaves contain several phenolic compounds, most important of which are oleo-European and hydroxytyrosol. The properties of the olive leaves have been attributed mainly to these two substances. The benefits of eating olive leaves (juice, snack) are summarized as follows: Strengthen the immune system. It is the predominant benefit of drinking olive juice or beverage because of its active ingredient, oleo-European. Multi-pathogenic efficacy can be beneficial in treating influenza viruses, herpes simplex has been pathogenetically linked to Alzheimer's disease, yeasts (Yeast Syndrome), bacteria (11 species). Spectacular results have also been reported in the treatment of acute symptoms of AIDS by the administration of olive leaves. Also, neuroinflammation is one of the pathological mechanisms of Alzheimer's Disease Antioxidant action. Inhibition of oxidation of LDL cholesterol, caused by olive leaf oil, reduces the risk of developing cardiovascular disease. The simultaneous presence of antioxidant vitamin E that is abundant in olive leaves, further enhances this action. Oxidative stress is a proven causative factor for Alzheimer's disease. Antihypertensive action. Since the 1950s, there have been clinical data on the use of olive leaves in the treatment of hypertension through their vasodilatory action. One of the environmental risk factors for Alzheimer's Disease is also Hypertension. Inhibition of platelet aggregation. This property turns olive leaves into a major weapon for treating cardiovascular events and avoiding dangerous thrombi. Vascular cerebral or cardiac events are also vascular environmental factors of Alzheimer's Disease Increase in energy - Treatment of chronic fatigue. Consumption of olive leaves has been reported by many patients, but also by healthy people, that it gives more energy. This greater potency, potentially, can increase performance at work, performance in sport. Also, many cases of rapid recovery from chronic fatigue with frequent and systematic consumption of olive leaves have been reported. In short, they are a very important tool for modern and stressed man, the need for wellness and longevity. One can easily observe the richness of olive leaves in trace elements, minerals - the role of Fe, Cu, Zn, Al and Hg in Alzheimer's disease is very important - and vitamins, making them a valuable nutritional tool for humans. At the same time, their fatty acid (saturated, monounsaturated, polyunsaturated) ratio is ideal and indicates their cardioprotective and neuroprotective properties. The presence of vitamin E is twice as high as that found in a proportion of sesame oil (4.1 mg / 100gr), making the olive leaves a food rich in that vitamin. As far as iron is concerned, its presence is greater than the corresponding presence of breakfast cereals (8.2mg / 100gr), so advertised as a complete and quality food for the modern man. Finally, particular reference should be made to the dietary fiber of the olive leaves. The dietary fiber is found in this food in abundance, making it a food that helps in the multifactorial treatment of constipation.

Official Title
-----------------
Management of Dementia With Olive Oil Leaves - GOLDEN

Conditions
-----------------
Prevention

Intervention / Treatment
-----------------
* Other: Beverage of Olive Oil Leaves
* Other: Mediterranean Diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Memory Complaints Abnormal memory function documented by scoring 1 SD below the age-adjusted mean on the Logical Memory II subscale, (Delayed Paragraph Recall) from the Wechsler Memory Scale-R. MMSE 18-24 CDR(sum of boxes) >= 0,5 Diagnosis: Mild Dementia (Alzheimer's Dementia) Geriatric Depression Scale (GDS) <6 Hachinski Modified Ischemic scale <= 4 Stability of Permitted Medications for 4 weeks Years of education: >= 5 Proficient language fluency Compliance Exclusion Criteria: Visual and auditory acuity inadequate for neuropsychological testing Enrollment in other trials or studies not compatible with MICOIL History of significant neurological or psychiatric illnesses or presence of other diseases precluding enrollment. Use of forbidden medications (listed below) Ferromagnetic implants and devices (including implants or devices held in place by sutures, granulation or ingrowth of tissue, fixation devices, or by other means) not eligible for MRI scanning. Brain malformation or other conditions that may complicate lumbar puncture Excluded Medication: Antidepressants with anti-cholinergic properties. Regular use of narcotic analgesics (>2 doses per week) within 4 weeks of screening. Use of neuroleptics with anti-cholinergic properties (e.g., chlorpromazine, thioridazine) within 4 weeks of screening. Chronic use of other medications with significant central nervous system anticholinergic activity within 4 weeks of screening (e.g., diphenhydramine). Use of Anti-Parkinsonian medications (including Sinemet, amantadine, bromocriptine, pergolide, selegeline) within 4 weeks of screening. Participation in any other investigational drug study within 4 weeks of screening (individuals may not participate in any drug study while participating in this protocol).

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Single Participant
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Beverage of Olive Oil Leaves<br>50 patients Beverage of Olive Oil Leaves | Other: Beverage of Olive Oil Leaves<br>* Beverage of Olive Oil Leaves,Oleuropein<br>|
| Active Comparator: Mediterranean dietary protocol Intervention<br>50 patients Dietary Supplement: Dietary Supplement:Mediterranean Diet | Other: Mediterranean Diet<br>* Mediterranean Diet ,for a personal nutrition with the same dietary habits<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neuropsychological Assessment - Measurements to Assess General Cognitive Function | Changes in Mini-Mental State Examination (MMSE) score Score scale:0-30,cut off:24 | baseline,24 months | 
| FUCAS-Measurements to Assess Daily Functionality | Changes in Functional cognitive assessment scale (FUCAS) score Score scale:42-126,cut off:42 | baseline,24 months | 
| Letter & Category Fluency Test- Measurement to Assess Verbal Fluency and Learning | Changes in the Letter & Category Fluency Test | baseline,24 months | 
| CDR- Measurements to Assess General Cognitive Function | Changes in Global Clinical Dementia Rating (CDR) score (sum of boxes) | baseline,24 months | 
| MoCA- Measurements to Assess General Cognitive Function | Changes in Montreal Cognitive Assessment (MoCA) | baseline,24 months | 
| Clock Drawing test- Measurements to Assess General Cognitive Function | Changes in the Clock Drawing test | baseline,24 months | 
| Logical Memory test- Measurements to Assess General Cognitive Function | Changes in the Logical Memory test | baseline, 24 months | 
| Digit Span Forward & Backward test- Measurements to Assess General Cognitive Function | Changes in the Digit Span Forward & Backward test | baseline,24 months | 
| WAIS-R (Wechler Adult Intelligence scele) Digit Symbol- Measurements to Assess General Cognitive Function | Changes in the WAIS-R Digit Symbol Substitution Test | baseline,24 months | 
| TMT(Trail Making Test) part A and B- Measurements to Assess General Cognitive Function | Changes in the Trail Making Test | baseline, 24 months | 
| ADASCog-Measurements to Assess Daily Functionality | Changes in Alzheimer's Disease Assessment Scale-Cognitive (ADASCog) Score scale:0-70,cut off:<15 | baseline, 24 months | 
| Functional Rating Scale for Dementia-Measurements to Assess Daily Functionality | Changes in Functional Rating Scale for Dementia (FRSSD) Score scale:0-6,cut off:>6 | baseline, 24 months | 
| Auditory Verbal Learning Test- Measurement to Assess Verbal Fluency and Learning | Changes in the Auditory Verbal Learning Test | baseline,24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NeuroImaging | Changes in brain Magnetic Resonance Imaging (MRI) 1.5 Tesla (brain atrophy) | baseline,24 months | 
| CSF - beta amyloid | Changes in mean values on high sensitivity beta-amyloid 1-42 protein | baseline,24 months | 
| CSF(cerebrospinal fluid) TAU-protein ( soluble protein) | Changes in mean values on TAU-protein in cerebrospinal fluid | baseline,24 months | 
| Electroencephalography recording | Changes in Electroencephalography (EEG), resting state.The device records brain signals through 57 electrodes, 2 reference electrodes attached to the earlobes, and a ground electrode placed at a left anterior position | baseline,24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
olive oil tree, leaves, Mild Dementia, prevention, Alzheimer's disease